RO4602522

DRUG5 trials

Sponsors

Hoffmann-La Roche

Conditions

Alzheimer's DiseaseHealthy VolunteerHealthy Volunteer, Alzheimer's Disease

Phase 1

A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers

CompletedNCT01625806

Hoffmann-La RocheHealthy Volunteer

Start: 2012-07-31End: 2012-12-31Updated: 2016-11-02

A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers

CompletedNCT01631422

Hoffmann-La RocheHealthy Volunteer

Start: 2012-06-30End: 2012-06-30Updated: 2016-11-02

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers

CompletedNCT01701089

Hoffmann-La RocheHealthy Volunteer, Alzheimer's Disease

Start: 2012-09-30End: 2013-05-31Updated: 2016-11-02

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

CompletedNCT02104648

Hoffmann-La RocheHealthy Volunteer

Start: 2014-04-30End: 2014-08-31Updated: 2016-11-02

Phase 2

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

CompletedNCT01677754

Hoffmann-La RocheAlzheimer's Disease

Start: 2012-10-24End: 2015-06-12Updated: 2017-05-30

Related Papers

Development and Psychometric Validation of the 27 Item Zarit CaregiverInterview for Alzheimer’s Disease (ZCI-AD-27)

Current Alzheimer Research2023-01-021 citations

Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).

2017-01-0132 citations

O3‐06‐06: Psychometric Validation of a Novel Scoring Algorithm for the Zarit Caregiver Interview for Alzheimer's Disease (ZCI‐AD)

Alzheimer s & Dementia2016-07-01